Chinese expert consensus statement on clinical diagnosis and treatment of fulminant myocarditis in adults

Chinese Journal of Cardiology

Volumn 45, Issue 9, 2017, Pages 742-752

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CHINESE; FULMINANT MYOCARDITIS; HUMAN; MYOCARDITIS;

EID: 85049126193     PISSN: 02533758     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0253-3758.2017.09.004     Document Type: Article

References (35)

1. ALP C, Malipiero G, Marcolongo R, et al. Myocarditis: a clinical overview. Curr Cardiol Rep, 2017, 19(7): 63. DOI: 10.1007/s11886-017-0870-x
2. Lazaros G, Oikonomou E, Tousoulis D. Established and novel treatment options in acute myocarditis, with or without heart failure. Expert Rev Cardiovasc Ther, 2017, 15(1): 25-34. DOI:10.1080/14779072.2017.1262764
3. Luyt CE, Hékimian G, Ginsberg F. What's new in myocarditis?. Intensive Care Med, 2016, 42(6): 1055-1057. DOI: 10.1007/s00134-015-4017-5
4. Fung G, Luo H, Qiu Y, et al. Myocarditis. Circ Res, 2016, 118(3): 496-514. DOI:10.1161/CIRCRESAHA.115.306573
5. Pollack A, Kontorovich AR, Fuster V, et al. Viral myocarditis-diagnosis, treatment options, and current controversies. Nat Rev Cardiol, 2015, 12(11): 670-680. DOI: 10.1038/nrcardio.2015.108
6. Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J, 2013, 34(33): 2636-2648, 2648a-2648d. DOI: 10.1093/eurheartj/eht210
7. Maisch B, Ruppert V, Pankuweit S. Management of fulminant myocarditis: a diagnosis in search of its etiology but with therapeutic options. Curr Heart Fail Rep, 2014, 11(2): 166-177. DOI: 10.1007/s11897-014-0196-6
8. Ginsberg F, Parrillo JE. Fulminant myocarditis. Crit Care Clin, 2013, 29(3): 465-483. DOI: 10.1016/j.ccc.2013.03.004
9. McCarthy RE, Boehmer JP, Hruban RH, et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med, 2000, 342(10): 690-695. DOI: 10.1056/NEJM200003093421003
10. Gupta S, Markham DW, Drazner MH, et al. Fulminant myocarditis. Nat Clin Pract Cardiovasc Med, 2008, 5(11): 693-706. DOI:10.1038/ncpcardio1331
11. Hufnagel G, Pankuweit S, Richter A, et al. The European study of epidemiology and treatment of cardiac inflammatory diseases (ESETCID). First epidemiological results. Herz, 2000, 25(3): 279-285.
12. Felker GM, Boehmer JP, Hruban RH, et al. Echocardiographic findings in fulminant and acute myocarditis. J Am Coll Cardiol, 2000, 36(1): 227-232.
13. Sun D, Ding H, Zhao C, et al. Value of SOFA, APACHE IV and SAPS II scoring systems in predicting short-term mortality in patients with acute myocarditis. Oncotarget, [2017-06-27]. http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path=18634&pubmed-linkout=1. published online ahead of print June 27, 2017
14. Chen J, Lai J, Yang L, et al. Trimetazidine prevents macrophage-mediated septic myocardial dysfunction via activation of the histone deacetylase sirtuin 1. Br J Pharmacol, 2016, 173(3): 545-561. DOI: 10.1111/bph.13386
15. Kühl U, Lassner D, von SJ, et al. Interferon-beta improves survival in enterovirus-associated cardiomyopathy. J Am Coll Cardiol, 2012, 60(14): 1295-1296. DOI: 10.1016/j.jacc.2012.06.026
16. Chen HS, Wang W, Wu SN, et al. Corticosteroids for viral myocarditis. Cochrane Database Syst Rev, 2013, (10): CD004471. DOI: 10.1002/14651858.CD004471.pub3
17. Bjelakovic B, Vukomanovic V, Jovic M. Fulminant myocarditis in children successfully treated with high dose of methyl-prednisolone. Indian J Pediatr, 2016, 83(3): 268-269. DOI: 10.1007/s12098-015-1831-2
18. Goland S, Czer LS, Siegel RJ, et al. Intravenous immunoglobulin treatment for acute fulminant inflammatory cardiomyopathy: series of six patients and review of literature. Can J Cardiol, 2008, 24(7): 571-574.
19. Drucker NA, Colan SD, Lewis AB, et al. Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation, 1994, 89(1): 252-257.
20. Kishimoto C, Shioji K, Hashimoto T, et al. Therapy with immunoglobulin in patients with acute myocarditis and cardiomyopathy: analysis of leukocyte balance. Heart Vessels, 2014, 29(3): 336-342. DOI: 10.1007/s00380-013-0368-4
21. Yu DQ, Wang Y, Ma GZ, et al. Intravenous immunoglobulin in the therapy of adult acute fulminant myocarditis: a retrospective study. Exp Ther Med, 2014, 7(1): 97-102. DOI: 10.3892/etm.2013.1372
22. Isogai T, Yasunaga H, Matsui H, et al. Effect of intravenous immunoglobulin for fulminant myocarditis on in-hospital mortality: propensity score analyses. J Card Fail, 2015, 21(5): 391-397. DOI: 10.1016/j.cardfail.2015.01.004
23. Ihdayhid AR, Chopra S, Rankin J. Intra-aortic balloon pump: indications, efficacy, guidelines and future directions. Curr Opin Cardiol, 2014, 29(4): 285-292. DOI: 10.1097/HCO.0000000000000075
24. Okai I, Inoue K, Maruyama M, et al. Transbrachial intra-aortic balloon pumping for a patient with fulminant myocarditis. Heart Vessels, 2012, 27(6): 639-642. DOI: 10.1007/s00380-012-0231-z
25. Lorusso R, Centofanti P, Gelsomino S, et al. Venoarterial extracorporeal membrane oxygenation for acute fulminant myocarditis in adult patients: a 5-year multi-Institutional experience. Ann Thorac Surg, 2016, 101(3): 919-926. DOI: 10.1016/j.athoracsur.2015.08.014
26. Diddle JW, Almodovar MC, Rajagopal SK, et al. Extracorporeal membrane oxygenation for the support of adults with acute myocarditis. Crit Care Med, 2015, 43(5): 1016-1025. DOI: 10.1097/CCM.0000000000000920
27. Nakamura T, Ishida K, Taniguchi Y, et al. Prognosis of patients with fulminant myocarditis managed by peripheral venoarterial extracorporeal membranous oxygenation support: a retrospective single-center study. J Intensive Care, 2015, 3(1): 5. DOI: 10.1186/s40560-014-0069-9
28. Hsu KH, Chi NH, Yu HY, et al. Extracorporeal membranous oxygenation support for acute fulminant myocarditis: analysis of a single center's experience. Eur J Cardiothorac Surg, 2011, 40(3): 682-688. DOI: 10.1016/j.ejcts.2010.12.050
29. Pozzi M, Banfi C, Grinberg D, et al. Veno-arterial extracorporeal membrane oxygenation for cardiogenic shock due to myocarditis in adult patients. J Thorac Dis, 2016, 8(7): E495-E502. DOI: 10.21037/jtd.2016.06.26
30. Schmidt M, Burrell A, Roberts L, et al. Predicting survival after ECMO for refractory cardiogenic shock: the survival after veno-arterial-ECMO (SAVE)-score. Eur Heart J, 2015, 36(33): 2246-2256. DOI: 10.1093/eurheartj/ehv194
31. Luyt CE, Landivier A, Leprince P, et al. Usefulness of cardiac biomarkers to predict cardiac recovery in patients on extracorporeal membrane oxygenation support for refractory cardiogenic shock. J Crit Care, 2012, 27(5): 524.e7-e14. DOI: 10.1016/j.jcrc.2011.12.009
32. Badawy SS, Fahmy A. Efficacy and cardiovascular tolerability of continuous veno-venous hemodiafiltration in acute decompensated heart failure: a randomized comparative study. J Crit Care, 2012, 27(1): 106.e7-106.e13. DOI: 10.1016/j.jcrc.2011.05.013
33. Felix SB, Beug D, Dörr M. Immunoadsorption therapy in dilated cardiomyopathy. Expert Rev Cardiovasc Ther, 2015, 13(2): 145-152. DOI: 10.1586/14779072.2015.990385
34. Jensen LD, Marchant DJ. Emerging pharmacologic targets and treatments for myocarditis. Pharmacol Ther, 2016, 161: 40-51. DOI: 10.1016/j.pharmthera.2016.03.006
35. Bulut D, Scheeler M, Wichmann T, et al. Effect of protein A immunoadsorption on T cell activation in patients with inflammatory dilated cardiomyopathy. Clin Res Cardiol, 2010, 99(10): 633-638. DOI: 10.1007/s00392-010-0162-6